Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Cash & Equivalents (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Cash & Equivalents for 11 consecutive years, with $4.5 billion as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 73.08% to $4.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 billion through Dec 2025, up 73.08% year-over-year, with the annual reading at $4.5 billion for FY2025, 73.08% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $4.5 billion at BeOne Medicines, up from $4.0 billion in the prior quarter.
  • The five-year high for Cash & Equivalents was $4.5 billion in Q4 2025, with the low at $310000.0 in Q2 2021.
  • Average Cash & Equivalents over 5 years is $2.7 billion, with a median of $2.8 billion recorded in 2024.
  • Peak annual rise in Cash & Equivalents hit 1461557.1% in 2022, while the deepest fall reached 99.98% in 2022.
  • Over 5 years, Cash & Equivalents stood at $328000.0 in 2021, then surged by 1179645.12% to $3.9 billion in 2022, then fell by 18.03% to $3.2 billion in 2023, then dropped by 17.16% to $2.6 billion in 2024, then soared by 73.08% to $4.5 billion in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $4.5 billion, $4.0 billion, and $2.8 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.